Molecular Partners And Orano Med Dose First Patients In DLL3-Targeting Radio-DARPin Small Cell Lung Cancer Study
Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712 Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.